AstraZeneca aims for $80bn revenue by 2030, highlighting oncology advances and growth potential. See AZN stock's valuation insights and GARP investment case.

The pharmaceutical leader has established itself as the leader in the fast-growing weight loss market. And although many ...

In this video, Matthew S. Davids, MD, said data from the BRUIN-313 trial supports front-line approval of pirtobrutinib in patients with previously untreated chronic lymphocytic leukemia or small ...

Eli Lilly And Company ($LLY) announced an update on their ongoing clinical study. Study Overview: Eli Lilly and Company is ...

For Jacob Van Naarden, Executive Vice President and President of Lilly Oncology, the mission is clear: bring better cancer ...

Combining elacestrant with targeted agents produced “clinically meaningful” outcomes for patients with locally advanced or metastatic ER-positive/HER2-negative breast cancer who have received at least ...

Eli Lilly ( LLY 2.00%) recently announced stellar results from a phase 3 clinical trial, Triumph-4, which evaluated efficacy ...

Take a look back into biotech in 2025 as the year is closing - from GLP-1s to radiopharmaceuticals and neuroplastogens.

Eli Lilly and Company (NYSE: LLY) is one of the most profitable NYSE stocks to buy right now. In a report released on ...

Eli Lilly leads incretins via Zepbound/Mounjaro, retatrutide at 28.7% loss, $50B R&D and US buildout, 2025 guidance, ...

Eli Lilly and Co shared updated results of Inluriyo (imlunestrant) from a Phase 3 study in previously treated breast cancer patients.

Alzheimer's trials testing Novo Nordisk’s blockbuster GLP-1 drug semaglutide, despite their failure, underscore a shift to ...